Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
NCT06744322

Fast Discharge After Acute Myocardial Infarction Discharge MI

Led by Medical University Innsbruck · Updated on 2026-03-16

2070

Participants Needed

8

Research Sites

265 weeks

Total Duration

On this page

AI-Summary

What this Trial Is About

To evaluate the hypothesis that a fast discharge strategy (discharge at 24 \[± 12\] hours) following invasive management for acute myocardial infarction is non-inferior to standard of care (\>36 hours) with respect to the risk of major adverse cardiovascular events (MACE) during follow-up.

CONDITIONS

Official Title

Fast Discharge After Acute Myocardial Infarction Discharge MI

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Uncomplicated acute myocardial infarction (NSTEMI and STEMI) diagnosed according to the 2023 acute coronary syndrome guidelines of the ESC
  • Age 18 years at time of consent
  • Invasive management strategy with successful PCI intervention of the culprit lesion defined by post-interventional TIMI 3 flow
  • Ability to understand and willing to sign written informed consent
Not Eligible

You will not qualify if you...

  • Myocardial infarction complicated by cardiac arrest
  • PCI-related complications including coronary perforation, side branch closure, inability to deliver stent/balloon, aortic dissection, allergic reaction grade 2, stroke/thromboembolism, access site complications
  • Malignant arrhythmias such as sustained ventricular arrhythmias and persistent bradycardia (<50 beats per minute), second-/third-degree atrioventricular block after PCI
  • Ongoing hemodynamic instability (systolic blood pressure <90 mmHg, elevated lactate, need for inotropes or vasopressors)
  • Ongoing respiratory instability defined by Killip class >I (rales, pulmonary edema)
  • Ongoing disorders of consciousness (somnolence, sopor, coma)
  • Acute kidney injury defined by KDIGO stages 2 and 3
  • Pregnancy
  • Untreated critical non-culprit lesions requiring revascularization during hospitalization
  • Immobility, limited mobility, or social situations preventing fast discharge as assessed by care team

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 8 locations

1

Hospital Wiener Neustadt

Wiener Neustadt, Lower Austria, Austria, 2700

Actively Recruiting

2

Cardinal Schwarzenberg Hospital Schwarzach

Schwarzach im Pongau, Schwarzach Im Pongau, Austria, 5620

Not Yet Recruiting

3

Paracelsus Medical University Salzburg

Salzburg, State of Salzburg, Austria, 5020

Actively Recruiting

4

Medical University of Graz

Graz, Styria, Austria, 8010

Actively Recruiting

5

Medical University of Innsbruck

Innsbruck, Tyrol, Austria, 6020

Actively Recruiting

6

University Teaching Hospital Wels-Grieskirchen

Wels, Upper Austria, Austria, 4600

Actively Recruiting

7

Academic Teaching Hospital Feldkirch

Feldkirch, Vorarlberg, Austria, 6800

Actively Recruiting

8

Ludwig Maximilian University Munich

Munich, Bavaria, Germany, 81377

Not Yet Recruiting

Loading map...

Research Team

M

Martin Reindl, MD, PhD

CONTACT

I

Ivan Lechner, MD, PhD

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

SINGLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

OTHER

Number of Arms

2

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here